Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 1.14B +201.1% |
| Revenue (ttm) | n/a |
| Net Income | -185.15M |
| EPS | -2.03 |
| Shares Out | 87.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 962,439 |
| Open | 12.81 |
| Previous Close | 12.90 |
| Day's Range | 12.63 - 13.24 |
| 52-Week Range | 3.89 - 36.26 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 41.82 (+219.24%) |
| Earnings Date | May 12, 2026 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $41.82, which is an increase of 219.24% from the latest price.
News
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology
Citi opened an “upside 90-day catalyst watch” on Olema Oncology (OLMA) while keeping a Buy rating on the shares with a $62 price target The company will present initial clinical…
Olema Oncology price target lowered to $35 from $38 at Guggenheim
Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $35 from $38 and keeps a Buy rating on the shares. The firm, which has updated its model for…
Olema Pharmaceuticals Quarterly report: Q1 2026
Olema Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Olema Pharmaceuticals Earnings release: Q1 2026
Olema Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Pharmaceuticals Proxy statement: Proxy filing
Olema Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Olema Pharmaceuticals Proxy statement: Proxy filing
Olema Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Olema Oncology (OLMA) with a Peer Perform rating and no price target Olema is pursuing development in second-line metastatic breast cancer and first-line mBC for…
Olema Oncology assumed with a Buy at Jefferies
Jefferies analyst Dennis Ding assumed coverage of Olema Oncology (OLMA) with a Buy rating and price target of $40, down from $43. The firm views Olema as a “high quality”…
Olema Oncology price target raised to $58 from $55 at JPMorgan
JPMorgan raised the firm’s price target on Olema Oncology (OLMA) to $58 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology…
Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Olema Oncology (OLMA) to $27 from $38 and keeps a Buy rating on the shares. Olema Oncology reported Q4…
Olema Oncology price target lowered to $38 from $40 at Guggenheim
Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $38 from $40 and keeps a Buy rating on the shares. Olema reiterated timelines for the Phase 3 palazestrant…
Olema Oncology price target raised to $62 from $60 at Citi
Citi raised the firm’s price target on Olema Oncology (OLMA) to $62 from $60 and keeps a Buy rating on the shares. The firm sees a favorable risk/reward into the…
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollme...
Olema Pharmaceuticals Annual report: Q4 2025
Olema Pharmaceuticals has published its Q4 2025 annual report on March 16, 2026.
Olema Pharmaceuticals Earnings release: Q4 2025
Olema Pharmaceuticals released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA.
Olema Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Palazestrant is advancing in pivotal trials for ER+/HER2- breast cancer, showing strong efficacy in both ESR1 mutant and wild type populations, with key readouts expected in fall and 2028. OP-3136, a selective KAT6 inhibitor, aims for improved tolerability and will present initial data in Q2.
Olema Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Recent data validate the efficacy of SERD/CERAN therapies in ER-positive, HER2-negative breast cancer, with palazestrant showing strong combinability and exposure. Ongoing trials and a robust pipeline, including a KAT6 inhibitor, position the company for significant market impact.
Olema Pharmaceuticals Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The summit highlighted the differentiation of palazestrant as a complete estrogen receptor antagonist with strong PK and tolerability, targeting both ESR1 wild-type and mutant breast cancer. Key trials OPERA-01 and OPERA-02 are progressing, with pivotal data expected in fall 2024 and late-decade, respectively.
Olema Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing palazestrant in two phase 3 trials for ER-positive, HER2-negative breast cancer, with a U.S. launch planned and significant market potential. Strong clinical data, strategic partnerships, and a new commercial focus position it for growth.
Olema Oncology initiated with a Buy at Stifel
Stifel initiated coverage of Olema Oncology (OLMA) with a Buy rating and $48 price target The firm, which “conservatively” models peak sales of $3.1B in 2035 for lead asset palazestrant,…